Chinese in Medical sector of Pakistan

[ghazi52]

,..,.

Xinjiang to deepen medical cooperation with Pakistan​

By Saira Iqbal
Sep 1, 2023

URUMQI - Recently, Pakistani Senator Rana Mahmood-ul-Hassan and his delegation visited Xinjiang Medical University and had a symposium with school president Haji Akber Aisa to further strengthen exchanges and cooperation between Pakistan and Xinjiang Medical University in the fields of education and scientific research.

"In our previous exchange with BRI countries, we learned that they are very interested in traditional Chinese medicine(TCM), including Uygur, Kazak and Mongolian medicine," said Haji Akber Aisa. Xinjiang Medical University’s medical exchanges with BRI countries started long ago, but there is a lack of a platform for all-round medical cooperation.

Earlier this year, at the first session of the 14th National People's Congress (NPC), Haji Akber Aisa put forward the proposal of carrying out an action plan for BRI medical science and technology innovation. Strengthening exchanges of international medical talent and building a bridge for mutual learning are important parts of the plan.

At the symposium, the two sides had in-depth discussions on education policies, student exchanges and other aspects. They also planned to build a platform for international education cooperation, further strengthening cooperation in scientific research, exchange of teachers and joint training of students.

“Our university has 30 years of experience in international education, with a mature system covering undergraduate and postgraduate stages. We have cultivated about 1,200 Pakistani students. In the future, we will strengthen interschool cooperation with Pakistan and collaborate in medical qualification examinations. We want to play a more active role in promoting medical research and talent training in BRI countries.” He added.

Haji Akber Aisa also suggested establishing high-quality overseas research and education centers in BRI countries and launching some mutually recognized technical norms and standards of TCM to facilitate resource sharing and improve the technological innovation capacity of the BRI countries. “With the internationalization of medical industry and advancement of medical science and technology, TCM will be integrated into the mainstream medical system of Belt and Road countries, and play a more important role in other aspects including economy, culture and ecology," he said.

 

[ghazi52]

.,.,.,

Pakistan-China tie-up in herbal medicines sought​

PCJCCI chief stresses need for setting up specialised research institute

Sept. 14, 2023

LAHORE: China has extensive expertise in herbal medicine manufacturing, an industry that is booming all around the world, and Pakistan should capitalise on the emerging opportunity, said a top official of a joint Pakistan-China chamber of commerce.

“Global market for herbal medicines is expected to reach $107 billion by the year 2024 and $178.4 billion by 2026, creating a vast room for Pakistan’s herbal medicine sector,” emphasised Pakistan-China Joint Chamber of Commerce and Industry (PCJCCI) President Moazzam Ghurki.

Chairing a think-tank session on Wednesday, Ghurki pointed out that almost 30,000 herbal drugs, cosmetic and healthcare goods producing companies were operating in Pakistan. “To empower this sector, the government should set up a specialised herbal research institution, which will not only help develop the industry but also educate health regulators.”

He added that China was a pioneer in herbal treatments based on research of more than 2,500 years, while Pakistan was rich in naturally growing herbs in its Himalayan range, which were of high value in the pharmaceutical industry.

 

[ghazi52]

.,.,.,

Pakistan highlights pharmaceutical collaboration with SCO countries​

China Economic Net
Sep 27, 2023

SUZHOU, “The 2nd SCO Pharmaceutical Cooperation Development Conference has demonstrated the commitment of member states to foster international cooperation in the pharmaceutical industry. Through this platform, SCO member states aim to promote mutual benefits, strengthen regulatory frameworks, encourage research and development collaboration, and expand market access,” highlighted Mr. Asim Rauf, CEO of Drug Regulatory Authority of Pakistan (DRAP).

Asim Rauf, who attended the conference in Suzhou on September 25 as a VIP guest, delivered a keynote address highlighting Pakistan’s commitment to promoting pharmaceutical development and regulation. In his address, he stressed the significance of cooperation among SCO member states in ensuring drug safety and advancing research and development in the pharmaceutical sector.

With the world facing unprecedented challenges, including the COVID-19 pandemic, the need for collaboration and partnership in the pharmaceutical sector has become even more critical. Pakistan and other SCO members are committed to working together to ensure the availability of essential medicines, strengthen health systems and improve the overall well-being of their populations.

The CEO took the opportunity to share Pakistan’s achievements in pharmaceutical regulation, highlighting the steps taken by DRAP to streamline the drug approval process, enhance quality control measures and promote transparency in the pharmaceutical industry.

“Pakistan has developed very rapidly in the field of regulation and the acceptance of its drugs is also increasing in the world. Especially during the pandemic, we have done a lot of work, including independent trials, starting the digitization process, introducing the CTD format, automating, etc,” the CEO added that “recently, we have noted the surge in Pakistan’s pharmaceutical exports as a result of these advances. We are ready to share the steps and experiences we have taken with other SCO member states.”

In an interview with China Economic Net, Mr. Asim Rauf touched on many potential areas of collaboration and partnership between Pakistan and other SCO member states in the pharma sector, most important of which is clinical trials at present.

Pakistan has various products from China including manufactured goods, high-tech products, cancer medicines, active pharmaceutical ingredients and medical devices. The CEO said there were many pending applications for clinical trials of Chinese medicines in Pakistan. He added that “we have generated a conducive environment where we have specifically invited Chinese companies to bring their products to Pakistan and import them.”

 

[ghazi52]

.,.,.,

Pakistan highlights pharmaceutical collaboration with SCO countries​

China Economic Net
Sep 27, 2023

SUZHOU- “The 2nd SCO Pharmaceutical Cooperation Development Conference has demonstrated the commitment of member states to foster international cooperation in the pharmaceutical industry.

Through this platform, SCO member states aim to promote mutual benefits, strengthen regulatory frameworks, encourage research and development collaboration, and expand market access,” highlighted Mr. Asim Rauf, CEO of Drug Regulatory Authority of Pakistan (DRAP).

Asim Rauf, who attended the conference in Suzhou on September 25 as a VIP guest, delivered a keynote address highlighting Pakistan’s commitment to promoting pharmaceutical development and regulation. In his address, he stressed the significance of cooperation among SCO member states in ensuring drug safety and advancing research and development in the pharmaceutical sector.

With the world facing unprecedented challenges, including the COVID-19 pandemic, the need for collaboration and partnership in the pharmaceutical sector has become even more critical. Pakistan and other SCO members are committed to working together to ensure the availability of essential medicines, strengthen health systems and improve the overall well-being of their populations.

The CEO took the opportunity to share Pakistan’s achievements in pharmaceutical regulation, highlighting the steps taken by DRAP to streamline the drug approval process, enhance quality control measures and promote transparency in the pharmaceutical industry.

“Pakistan has developed very rapidly in the field of regulation and the acceptance of its drugs is also increasing in the world. Especially during the pandemic, we have done a lot of work, including independent trials, starting the digitization process, introducing the CTD format, automating, etc,” the CEO added that “recently, we have noted the surge in Pakistan’s pharmaceutical exports as a result of these advances. We are ready to share the steps and experiences we have taken with other SCO member states.”

In an interview with China Economic Net, Mr. Asim Rauf touched on many potential areas of collaboration and partnership between Pakistan and other SCO member states in the pharma sector, most important of which is clinical trials at present.

Pakistan has various products from China including manufactured goods, high-tech products, cancer medicines, active pharmaceutical ingredients and medical devices. The CEO said there were many pending applications for clinical trials of Chinese medicines in Pakistan. He added that “we have generated a conducive environment where we have specifically invited Chinese companies to bring their products to Pakistan and import them.”

In addition to attending the conference, Mr. Asim Rauf held bilateral meetings with representatives from other SCO member states to explore opportunities for collaboration in the pharmaceutical sector. He noted that “the conference provided a platform where we can individually sign bilateral MoUs and agreements with all other member countries, so that we can bind each other and share knowledge on those global issues that may affect public safety and people’s health.”


These meetings aimed to foster closer ties and facilitate the exchange of knowledge and expertise in areas such as drug regulation, quality control, and capacity building. The conference provided a platform for participants to exchange best practices, discuss regulatory challenges and explore avenues for future collaboration. Experts from SCO member countries shared their experiences and insights on topics such as drug registration, pharmacovigilance and pharmaceutical research and development.

The conference concluded with the Suzhou Initiative, injecting new and strong impetus into the building of an even closer SCO community of shared future. The health and pharmaceutical regulatory authorities, relevant institutions and industries of the participating countries attach great importance to cooperation in the field of medicine and health among the SCO member states, observer states and dialogue partners, and will actively play the role of the SCO mechanism as a platform.